[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Bölke E, Peiper M, Matuschek C, Schieren G, Glombick R, Förster C, Budach W, Orth K: Extranodal diffuse non hodgkin lymphoma in the thigh. Eur J Med Res; 2010 Aug 20;15(8):367-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal diffuse non hodgkin lymphoma in the thigh.
  • Diffuse large B-cell lymphoma usually starts as a rapidly growing mass in an internal lymph node and can grow in other areas such as the bone or intestines.
  • Biopsies of the tumour revealed diffuse proliferation of large lymphoid cells which have totally affected the normal architecture of striated muscle.
  • The patient received multimodality treatment including chemotherapy of the CHOP regimen and adjuvant radiotherapy.
  • Despite this being a fast growing lymphoma, about 3 out of 4 people will have no signs of disease after initial treatment, and about half of all people with this lymphoma are cured with therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Thigh

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):422-9 [20038237.001]
  • [Cites] Crit Rev Oncol Hematol. 2011 Apr;78(1):59-72 [20303778.001]
  • [Cites] Prague Med Rep. 2010;111(1):5-11 [20359433.001]
  • [Cites] Drugs Aging. 2010 Mar 1;27(3):211-38 [20210368.001]
  • (PMID = 20947475.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3458703
  •  go-up   go-down


2. Takeuchi Y, Sawada Y, Yabuki D, Masuda E, Satou D, Iwasawa T, Kuroda K, Tajima M, Matsushima M: [Testicular malignant lymphoma: a case report]. Hinyokika Kiyo; 2003 Nov;49(11):675-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular malignant lymphoma: a case report].
  • We report a case of malignant lymphoma arising from the testicle in a patient who had been on chemotherapy for a long period after orchiectomy.
  • According to the histopathological diagnosis, the tumor was classified as non-Hodgkin's lymphoma, diffuse large cell type, B cell type.
  • Four courses of cycrophosphamide, adriamycin, vincristin and prednisolone (CHOP) therapy were administered.
  • COP (CHOP minus adriamycin) therapy has been given every four months on an out-patient basis.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse. Testicular Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Orchiectomy. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14719457.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


3. Sehn LH, Connors JM: Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology (Williston Park); 2005 Apr;19(4 Suppl 1):26-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
  • The most common subtype of aggressive non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL).
  • Diffuse large B-cell lymphoma represents a heterogeneous entity, with 5-year overall survival rates ranging from 26% to 73%.
  • Approximately 25% of patients with DLBCL present with limited-stage disease and are treated with combined-modality therapy (brief chemotherapy and involved-field radiation).
  • Most patients present with advanced-stage disease and require treatment with an extended course of chemotherapy.
  • The CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone) chemotherapy regimen has been the mainstay of therapy since its development in the 1970s, as more intensive chemotherapy regimens failed to show additional benefit.
  • The era of monoclonal antibodies has transformed treatment practices for aggressive lymphoma and has led to a significant improvement in outcome.
  • A randomized trial comparing the use of rituximab (Rituxan), a chimeric anti-CD20 IgG1 monoclonal antibody, combined with CHOP chemotherapy vs CHOP chemotherapy alone for elderly patients with advanced-stage DLBCL demonstrated a significant benefitfor the combination approach.
  • Despite this advance, newer therapies are needed and many are under active investigation.
  • The insights gained from molecular techniques such as gene expression profiling should permit identification of additional lymphoma-specific therapeutic targets and the development of novel agents that take into account underlying biology and allow for greater tailoring of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934515.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 58
  •  go-up   go-down


Advertisement
4. Yoon JH, Lee YY, Park CG, Koe BH, Kim IS: A case of primary adrenal gland lymphoma. Korean J Intern Med; 2003 Jun;18(2):122-4
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary adrenal gland lymphoma.
  • Primary adrenal lymphoma is extremely rare.
  • We describe a case of non-Hodgkin's lymphoma of diffuse large B-cell type with right adrenal involvement.
  • The patient received chemotherapy and external irradiation and achieved complete remission of the disease.
  • We describe the case of primary adrenal lymphoma with a review of the literature on this unusual neoplasm.
  • Primary adrenal lymphoma should be included in the differential diagnosis of adrenal mass.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872452.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC4531612
  •  go-up   go-down


5. Hernàndez DE, Hernàndez AE: Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor. Eur J Cancer Care (Engl); 2006 Dec;15(5):493-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated diffuse non-Hodgkin's lymphoma in Venezuelan patients: treatment with full-dose cyclophosphamide-doxorubicin-vincristine-prednisone without routine use of granulocyte-colony stimulating factor.
  • The routine use of granulocyte-colony stimulating factor (G-CSF) for 10 days during full-dose cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy in HIV-associated diffuse non-Hodgkin's lymphoma (NHL) patients is very expensive in developing countries.
  • We treated 22 HIV-associated diffuse NHL patients with standard-dose CHOP and used G-CSF after an episode of febrile neutropenia until neutrophil count reached 1000/mm3.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Fever / chemically induced. Fever / prevention & control. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neutropenia / chemically induced. Neutropenia / prevention & control. Prednisone / administration & dosage. Prednisone / adverse effects. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177909.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Azuma T, Ozaki E, Yakushijin Y, Kohno M, Sakai I, Takada K: [Esophageal stricture following complete remission after chemotherapy for malignant lymphoma in an elderly patient]. Nihon Ronen Igakkai Zasshi; 2006 Jul;43(4):531-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esophageal stricture following complete remission after chemotherapy for malignant lymphoma in an elderly patient].
  • A 75-year-old woman was given a diagnosis of malignant lymphoma (non-Hodgkin, diffuse large B cell type, stage IIA) at our hospital on August 2003.
  • She received six courses of rituximab-based chemotherapy (R-CHOP regimen) and then she achieved complete remission.
  • We report here a case of esophageal stricture following complete remission after chemotherapy for malignant lymphoma in an elderly patient.
  • [MeSH-major] Esophageal Stenosis / diagnosis. Esophageal Stenosis / etiology. Lymphoma / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Esophagectomy. Esophagitis, Peptic / complications. Female. Fractures, Compression / complications. Hernia, Hiatal / complications. Humans. Laparoscopy. Remission Induction. Risk Factors. Rituximab. Spinal Fractures / complications

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937948.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Ptushkin VV, Chimishkian KL, Zhukov NV, Osmanov DSh, Andreeva LIu, Tupitsyn NN, Larionova VB, Mkheidze DM, Poddubnaia NV: [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells]. Ter Arkh; 2003;75(1):65-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
  • AIM: To study efficacy of rituximab in patients with resistant B-cell lymphoma on high-dose chemotherapy.
  • MATERIAL AND METHODS: From September 2000 to April 2002 we studied efficacy and tolerance of rituximab at different stages of high-dose chemotherapy.
  • The treatment was given to 10 patients with histologically verified CD20+ non-Hodgkin's lymphoma: diffuse large-cell (n = 4), Berkitt's (n = 2), follicular (n = 3), mantle-cell (n = 1).
  • Five patients with diffuse large-cell lymphoma and Berkitt's lymphoma had a primary resistant course of the disease, one patient with diffuse large-cell lymphoma had a refractory recurrence.
  • The patients received 1-2 courses of induction chemotherapy with dexa-BEAM with collection of peripheral stem cells followed by high-dose chemotherapy (BEAM-9, CBV + mitoxantron-1) with transplantation of autologous stem blood cells.
  • Rituximab infusion (375 mg/m2) was conducted before the collection of the stem cells, prior to high-dose chemotherapy and in posttransplantation period after recovery of hemopoiesis.
  • 5 patients are in complete remission: 2 of them without further treatment, 3-after progression and repeat therapy including rituximab and interferon-alpha or rotuximab and CHOP chemotherapy.
  • CONCLUSION: The addition of rituximab can improve the results of high-dose chemotherapy of patients with non-Hodgkin's lymphoma resistant to standard doses of cytostatics.
  • Repeat use of this drug can be effective in some patients with progression after high-dose chemotherapy with rituximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Rituximab

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12652962.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


8. Hill M, Kyle F: NHL (diffuse large B-cell lymphoma). BMJ Clin Evid; 2010;2010
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NHL (diffuse large B-cell lymphoma).
  • INTRODUCTION: Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line treatments for aggressive, or for relapsed aggressive, non-Hodgkin's lymphoma (diffuse large B-cell lymphoma)?
  • We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
  • CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: allogeneic stem-cell support, chemotherapy (conventional dose salvage, high-dose plus autologous transplant stem-cell support, conventional dose in people with chemosensitive disease), CHOP 14, CHOP 21, CHOP 21 with radiotherapy, CHOP 21 with rituximab, ACVBP, MACOP-B, m-BACOD, PACEBOM, and ProMACE-CytaBOM.
  • [MeSH-minor] Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Rituximab

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Med Oncol. 2005;22(4):383-7 [16260856.001]
  • [Cites] Haematologica. 2006 Jan;91(1):96-103 [16434377.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):161-76 [17240533.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2759-66 [17132720.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Apr;22(2):194-9 [17600466.001]
  • [Cites] Med Oncol. 2007;24(1):85-9 [17673816.001]
  • [Cites] Cancer J. 2007 Sep-Oct;13(5):327-34 [17921732.001]
  • [Cites] Blood. 2008 Jan 15;111(2):537-43 [17971487.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:71-5 [9187435.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 7:102-16 [9154102.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):303-7 [11161392.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]
  • [Cites] Eur J Haematol. 2008 Jun;80(6):477-82 [18331601.001]
  • [Cites] Expert Opin Pharmacother. 2008 Sep;9(13):2247-58 [18710350.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1079-86 [10572606.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:87-90 [10707786.001]
  • [Cites] Acta Oncol. 2001;40(2-3):198-212 [11441932.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(6):308-31 [11464975.001]
  • [Cites] An Esp Pediatr. 2001 Sep;55(3):230-8 [11676898.001]
  • [Cites] Ann Intern Med. 2002 Jan 15;136(2):144-52 [11790067.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3744-53 [12963703.001]
  • [Cites] Acta Oncol. 2003;42(5-6):605-19 [14596518.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1385-9 [15359637.001]
  • [Cites] Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82 [15361313.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Blood. 1990 Nov 15;76(10):2153-8 [1700732.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):769-78 [7512131.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:91-5 [7515652.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):318-22 [8688344.001]
  • [Cites] Eur J Haematol. 1996 Nov;57(5):377-83 [9003479.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • (PMID = 21406125.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC3217796
  •  go-up   go-down


9. Pels H, Deckert-Schlüter M, Glasmacher A, Kleinschmidt R, Oehring R, Fischer HP, Bode U, Schlegel U: Primary central nervous system lymphoma: a clinicopathological study of 28 cases. Hematol Oncol; 2000 Mar;18(1):21-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma: a clinicopathological study of 28 cases.
  • A group of 28 consecutive patients (mean age 59 years) with primary central nervous system lymphoma (PCNSL) was treated with different regimens, including steroids only, radiotherapy (RT), chemotherapy or combinations of all.
  • Lymphoma was classified as high grade malignant B-cell non-Hodgkin's lymphoma of the diffuse large cell type in each of these cases.
  • RT alone led to tumour remission in more than 70 per cent, survival could be prolonged with additional chemotherapy.
  • Thirteen patients were treated with chemotherapy alone; nine of them received a novel combined intraventricular and systemic polychemotherapy protocol based on high dose methotrexate (MTX) and high dose cytarabine (ara-C).
  • Neurotoxicity, i.e. white matter lesions associated with severe cognitive dysfunction affected both patients surviving RT more than a year and patients treated with combination RT/chemotherapy.
  • Confluent white matter hyperintense lesions were detectable on MRI in three out of 13 patients treated with chemotherapy alone, however, cognitive dysfunction has not been detected in these patients.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Cognition Disorders / etiology. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Follow-Up Studies. Humans. Injections, Intraventricular. Male. Methotrexate / administration & dosage. Middle Aged. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / therapy. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Ltd.
  • (PMID = 10797527.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, Guy G, Lapierre F: Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg; 2000 Feb;92(2):261-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracerebral malignant lymphoma: report of 248 cases.
  • OBJECT: The authors present a retrospective analysis of 248 immunocompetent patients with primary intracerebral lymphoma treated at 19 French and Belgian medical centers between January 1980 and December 1995.
  • All tumors available for review were classic diffuse non-Hodgkin's lymphoma, for which the phenotype was determined in 220 patients: 212 (96.4%) were B-cell and eight (3.6%) were T-cell type tumors.
  • According to the Revised European-American classification of lymphoid neoplasms, most lesions were diffuse large cell tumors (62%).
  • A total of 196 tumors were reviewed in 127 patients for whom preoperative computerized tomography and magnetic resonance studies were available.
  • Of the 248 patients studied, 129 (52%) received chemotherapy plus radiation therapy, 60 (24%) received radiation therapy alone, 35 (14%) received chemotherapy alone, and 24 (10%) received no postsurgical treatment.
  • CONCLUSIONS: Using univariate analysis, the authors determined prognostic factors that were significantly associated with a favorable impact on survival including age younger than 60 years, radiation therapy (without evidence of a dose-response relationship), radiation therapy combined with chemotherapy, and chemotherapy consisting of anthracycline.
  • Multivariate analysis was used to confirm the independent prognostic value of radiation therapy, age, chemotherapy consisting of anthracyclines or methotrexate, and partial surgical resection.
  • This European survey provides a reasonable basis for the treatment of primary intracerebral lymphoma with the following sequence: stereotactic biopsy sampling, chemotherapy with a methotrexate- and anthracycline-based regimen, followed by cranial irradiation.
  • [MeSH-major] Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / pathology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10659013.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Epure C, Ionascu L, Hagima N, Nan S, Stefaniu I: [Malignant non-Hodgkin diffuse lymphoma with extranodal orbital involvement--a clinical case]. Oftalmologia; 2005;49(4):29-32
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant non-Hodgkin diffuse lymphoma with extranodal orbital involvement--a clinical case].
  • The subsequent evolution of the disease required extensive investigations which provide the definitive diagnosis of non-Hodgkin, diffuse B-cell lymphoma, with extranodal orbital involvement.
  • In this case, the treatment of choice it must be systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Diagnosis, Differential. Female. Humans. Middle Aged. Prednisone / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524121.001).
  • [ISSN] 1220-0875
  • [Journal-full-title] Oftalmologia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Oftalmologia
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Qin L, Shi JH, Liu HR, Feng RE, Liu T, Li J, Lü W, Qin MW: [Non-Hodgkin's lymphoma with diffuse ground-glass opacity on chest CT: a report of 6 cases]. Zhonghua Yi Xue Za Zhi; 2010 Dec 14;90(46):3283-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphoma with diffuse ground-glass opacity on chest CT: a report of 6 cases].
  • OBJECTIVE: To investigate the clinical, pathological and imaging characteristics, misdiagnosis and treatment of pulmonary non-Hodgkin's lymphoma with diffuse ground-glass opacities (GGO).
  • METHODS: Six cases of pulmonary non-Hodgkin's lymphoma with diffuse GGO on chest CT diagnosed from January 2008 to March 2010 were retrospectively analyzed.
  • Chest CT showed diffuse GGO (n=2), diffuse GGO with consolidations (n=3), with wide lung septum (n=3), with multiple nodules (n=2), with enlargement of mediastinal lymph nodes (n=2).
  • Histological findings including intravascular lymphoma (n=2), diffuse large B cell lymphoma (n=2) and T cell lymphoma (n=2).
  • Chemotherapy was administered in 4 patients with B cell lymphoma and all of them improved or remained stable.
  • One patient with T cells lymphoma was lost to follow-up and another patient with T cell lymphoma died due to lung infection.
  • CONCLUSIONS: Non-Hodgkin's lymphoma with diffuse GGO on chest CT scan is rare.
  • [MeSH-major] Lung / radiography. Lung Neoplasms / radiography. Lymphoma, Non-Hodgkin / radiography
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223788.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Eissa LA, Esmaeel MI: Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma. Pak J Pharm Sci; 2008 Jan;21(1):29-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of some serum biomarkers (E cadherin, GAGs & MDA in patients with diffuse large B-cell lymphoma.
  • This study aimed to estimate the pretreatment serum levels of SVE-Cadherin, glycosaminoglycams (GAGs) and malondialdehyde (MDA) in order to evaluate their prognostic significance and their role in monitoring tumor response and overall-survival in Non Hodgkin lymphoma (DLCL) patients.
  • For this purpose pretreatment serum levels of these biochemical markers were evaluated in 40 newly diagnosed patients with non-Hodgkin lymphoma (Diffuse large cell type) and studied in relation to expression in healthy control.
  • Regarding response to therapy, only MDA showed a significant relation with response of the patient to treatment.
  • High level of MDA may be used as a predictor for tumor response to systemic chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / blood. Cadherins / blood. Glycosaminoglycans / blood. Lymphoma, Large B-Cell, Diffuse / blood. Malondialdehyde / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166516.001).
  • [ISSN] 1011-601X
  • [Journal-full-title] Pakistan journal of pharmaceutical sciences
  • [ISO-abbreviation] Pak J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Glycosaminoglycans; 4Y8F71G49Q / Malondialdehyde
  •  go-up   go-down


14. Hughes M, Morrison A, Jackson R: Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma; 2005 Jun;46(6):873-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature.
  • Primary bladder non-Hodgkin's lymphoma (NHL) is rare.
  • Using the Scotland and Newcastle lymphoma group database, 12 patients with primary bladder lymphoma were identified between 1980 and 2001, the largest single group of patients available to date.
  • Six cases were low-grade extranodal marginal zone lymphoma, 4 diffuse large B-cell lymphoma, one an ALK 1 positive anaplastic large cell lymphoma (ALKoma) and one a low-grade lymphoma unspecified.
  • One patient with high-grade NHL gained complete remission without conventional therapy.
  • Nine patients were treated with single or combined modality surgery, chemotherapy and/or radiotherapy.
  • A review of 88 additional cases in the literature support the findings that primary bladder lymphoma is associated with a good prognosis.
  • Patients with low-grade extranodal marginal zone lymphoma may respond well to simple therapies.
  • Patients with diffuse large B-cell lymphoma respond well to first-line chemotherapy regimens.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Oncology / methods. Prognosis. Registries. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019532.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Nagasaki A, Miyagi T, Nakazato T, Taira N, Ohshima K, Kikuchi M, Takasu N, Masauda M: Very late central nervous system relapse in a patient with B cell lymphoblastic lymphoma. Acta Haematol; 2004;112(4):212-6
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late central nervous system relapse in a patient with B cell lymphoblastic lymphoma.
  • Very late relapse of lymphoblastic lymphoma (LBL) is very rare.
  • We report a case of a patient who developed central nervous system (CNS) relapse of LBL 16 years after the onset of the primary disease.
  • Examination of a biopsy of the skin tumor showed typical features of non-Hodgkin's lymphoma (diffuse medium-sized cell type).
  • She received multiagent chemotherapy and went into remission.
  • A midline suboccipital craniotomy was performed and pathological examination revealed a diffuse proliferation of lymphoid cells, which were positive for terminal deoxynucleotidyl transferase, but negative for CD45RO, CD3 and CD20.
  • Thus, the original diagnosis of diffuse medium-sized lymphoma was revised to B cell LBL.
  • After salvage chemotherapy, the patient underwent high-dose chemotherapy with autologous peripheral blood stem cell support and subsequent craniospinal irradiation.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Cell Proliferation. Child. Combined Modality Therapy. Female. Humans. Immunophenotyping. Magnetic Resonance Imaging. Neoplasm Invasiveness. Peripheral Blood Stem Cell Transplantation. Recurrence. Salvage Therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564734.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Watanabe I, Yakushijin Y, Sakai I, Yasukawa M, Fujita S: [Granulocytic sarcoma developing in lymph nodes]. Rinsho Ketsueki; 2002 May;43(5):378-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was initially diagnosed as having non-Hodgkin lymphoma, diffuse large cell type, Ann Arbor stage IV, and transferred to our hospital for chemotherapy.
  • The diagnosis of malignant lymphoma was therefore confirmed.
  • The patient, was treated with THP-COP therapy, which proved very effective.
  • On basis of these findings and the previous results of flow cytometry, we changed the diagnosis from malignant lymphoma to granulocytic sarcoma.
  • THP-COP therapy was continued, and complete remission was achieved.
  • Two months later, however, the patient developed acute myelocytic leukemia (AML M1) and received DCP therapy, but he died of pneumonia.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / pathology. Male. Neoplasms, Second Primary / etiology. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12096491.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


17. Kyle F, Hill M: NHL (diffuse large B cell lymphoma). BMJ Clin Evid; 2008;2008
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NHL (diffuse large B cell lymphoma).
  • INTRODUCTION: Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the UK; 9443 new cases were diagnosed in the UK in 2002, and it caused 4418 UK deaths in 2003.
  • METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line treatments for aggressive, or for relapsed aggressive, non-Hodgkin's lymphoma (diffuse large B cell lymphoma)?
  • We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
  • CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: allogeneic stem cell support, chemotherapy (conventional dose salvage, high-dose plus autologous transplant stem cell support, conventional dose in people with chemosensitive disease), CHOP 14, CHOP 21, CHOP 21 with radiotherapy, CHOP 21 with rituximab, MACOP-B, m-BACOD, PACEBOM, and ProMACE-CytaBOM.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Neoplasm Recurrence, Local
  • [MeSH-minor] Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Rituximab. Salvage Therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2001;40(2-3):198-212 [11441932.001]
  • [Cites] Med Oncol. 2005;22(4):383-7 [16260856.001]
  • [Cites] An Esp Pediatr. 2001 Sep;55(3):230-8 [11676898.001]
  • [Cites] Ann Intern Med. 2002 Jan 15;136(2):144-52 [11790067.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3744-53 [12963703.001]
  • [Cites] Acta Oncol. 2003;42(5-6):605-19 [14596518.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4284-9 [12920037.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1385-9 [15359637.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Blood. 1990 Nov 15;76(10):2153-8 [1700732.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):769-78 [7512131.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:91-5 [7515652.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):318-22 [8688344.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 1999 Sep;10(9):1079-86 [10572606.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:87-90 [10707786.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):303-7 [11161392.001]
  • [Cites] Eur J Haematol. 1996 Nov;57(5):377-83 [9003479.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 7:102-16 [9154102.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:71-5 [9187435.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Haematologica. 2006 Jan;91(1):96-103 [16434377.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(6):308-31 [11464975.001]
  • (PMID = 19450335.001).
  • [ISSN] 1752-8526
  • [Journal-full-title] BMJ clinical evidence
  • [ISO-abbreviation] BMJ Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2907930
  •  go-up   go-down


18. Yoshinaga K, Teramura M, Iwabe K, Kobayashi S, Masuda M, Motoji T, Mizoguchi H: Anti-lymphoma effect of naproxen and indomethacin in a patient with relapsed diffuse large B-cell lymphoma. Am J Hematol; 2001 Mar;66(3):220-3
Hazardous Substances Data Bank. INDOMETHACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-lymphoma effect of naproxen and indomethacin in a patient with relapsed diffuse large B-cell lymphoma.
  • A 77-year-old man with relapsed non-Hodgkin's lymphoma, diffuse large B-cell type, was treated with naproxen, a nonsteroidal anti-inflammatory drug (NSAID), for paraneoplastic fever.
  • When relapse of lymphoma occurred in spite of continuous naproxen administration, indomethacin, another type of NSAID, was tried.
  • Surprisingly, rapid regression of lymphoma occurred again and was maintained for almost 1 year.
  • These results indicate that NSAIDs are effective in some patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Indomethacin / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Naproxen / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. NAPROXEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11279630.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 57Y76R9ATQ / Naproxen; XXE1CET956 / Indomethacin
  •  go-up   go-down


19. Portlock CS, Hamlin P, Noy A, Chey W, Gaydos CA, Palomba L, Schwartz I, Corcoran S, Rosenzweig L, Walker D, Papanicolaou G, Markowitz A: Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy. Ann Oncol; 2008 Feb;19(2):254-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.
  • BACKGROUND: Eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tumor can result in lymphoma remission.
  • We prospectively identified/treated infections in nonbulky, advanced stage indolent lymphoma (follicular; nonfollicular lymphoma) eligible for observation.
  • MATERIALS AND METHODS: Stool H. pylori, hepatitis C and Borrelia serologies, Borrelia and Chlamydia fixed tissue PCR, Chlamydia peripheral blood mononuclear cell PCR and hydrogen breath test for small bowel bacterial overgrowth (SBBO) were obtained.
  • Lymphoma responses to antimicrobial therapy: H. pylori [one complete response (CR), 24+ months; one transient near CR]; hepatitis C [two CRs, 18+ and 30+ months; one partial response (PR) but hepatitis C virus persistent]; SBBO (one PR, 30+ months).
  • Patients with associated infections, but without lymphoma CR, have required lymphoma treatment sooner than those without initial infections (treatment-free survival at 23.4 months median follow-up, 40.5% versus 74.7%, P = 0.01), indicating a different biology.
  • CONCLUSION: Infections are common in advanced stage indolent lymphoma (37.5% in our series).
  • Anecdotal lymphoma responses have been seen and three have been durable CRs (18 to 30+ months) with infection eradication alone.
  • The identification and treatment of associated infections may be a first step towards developing a lymphoma prevention strategy.


20. Pascual JM, González-Llanos F, Roda JM: Primary hypothalamic-third ventricle lymphoma. Case report and review of the literature. Neurocirugia (Astur); 2002 Aug;13(4):305-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hypothalamic-third ventricle lymphoma. Case report and review of the literature.
  • She had a diffuse and homogeneous tumoral lesion involving the third ventricle and the adjacent hypothalamic area with marked enhancement after contrast administration on both, competed tomography scan and magnetic resonance images.
  • Histological diagnosis proved to be a diffuse non-Hodgkin lymphoma and the patient subsequently was treated with adjuvant radiotherapy and chemotherapy.
  • Treatment of PCNSL remains a challenge, and the topographical location within the hypothalamic-third ventricle area is even more complex.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Hypothalamus / pathology. Lymphoma, Non-Hodgkin / pathology. Third Ventricle / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12355653.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 36
  •  go-up   go-down


21. Hasegawa Y, Shirai S, Mishina T, Nakata M, Aikawa K, Yoshida K: [An elderly non-Hodgkin lymphoma patient with a massive tumor of the heart]. Rinsho Ketsueki; 2002 Jul;43(7):538-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly non-Hodgkin lymphoma patient with a massive tumor of the heart].
  • We report on an elderly patient with a malignant lymphoma forming a huge mass in the heart.
  • She was diagnosed as having non-Hodgkin lymphoma, diffuse large cell type, B-cell type.
  • Computed tomography scans showed a markedly thickened right ventricular wall of the heart, swollen lymph nodes of the mediastinum, bilateral pleural effusions, and a tumor in the spleen.
  • Lymphoma cells were found in the pleural effusion, and the lymphoma was diagnosed as clinical stage IV.
  • EF increased to 70% after 3 courses of chemotherapy with CHOP regimen.
  • All lesions disappeared after 6 courses of chemotherapy were completed.
  • After consolidative radiotherapy with a total dose of 37 Gy to the mediastinum and heart, bilateral pleural effusions, elevation of the patient's lactate dehydrogenase level and soluble IL-2 receptor value were recognized, which suggested relapse of the lymphoma, although histopathological confirmation could not be realized.
  • [MeSH-major] Heart Neoplasms / therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy

  • Genetic Alliance. consumer health - Heart tumor.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229122.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Novella G, Porcaro AB, Righetti R, Cavalleri S, Beltrami P, Ficarra V, Brunelli M, Martignoni G, Malossini G, Tallarigo C: Primary lymphoma of the epididymis: case report and review of the literature. Urol Int; 2001;67(1):97-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the epididymis: case report and review of the literature.
  • OBJECTIVE: To report an extremely rare clinical pathological observation of a case of primary lymphoma of the epididymis, without testicular or systemic involvement, and to update the relevant literature.
  • Epididymitis was diagnosed and conservative therapy with antibiotics and anti-inflammatory drugs was given.
  • After 2 months of therapy the patient was admitted to our department because a tumor was suspected.
  • RESULTS: High-grade primary epididymal non-Hodgkin's lymphoma with diffuse large cells (group G according to the Working Formulation) was diagnosed.
  • Clinical pathological staging detected stage IE (extranodal) primary epididymal lymphoma.
  • The patient was referred to the Hematologic Unit for combined chemotherapy, according to the VACOP-B protocol.
  • CONCLUSIONS: When an epididymal mass does not benefit from medical treatment, scrotal exploration and fresh frozen sections of the lesion should be done.
  • The possible bilateral involvement by primary epididymal lymphoma has to be kept in mind.
  • Radical orchiectomy is the treatment of choice for primary lymphoma of the epididymis.
  • Adjuvant chemotherapy is indicated in high-grade malignant lymphoma.
  • [MeSH-major] Epididymis. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11464129.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 5
  •  go-up   go-down


23. Kragelund CB, Søndergaard L, Bjerrum OW: [Primary cardiac lymphoma]. Ugeskr Laeger; 2001 Feb 26;163(9):1289-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma].
  • Primary cardiac non-Hodgkin lymphoma is very rare.
  • Results recently published suggest that the prognosis is good, if the lymphoma is diagnosed early.
  • A myocardial biopsy showed malignant non-Hodgkin lymphoma of the diffuse, large cell B-type.
  • The patient was treated with chemotherapy and control MRI after four treatments showed complete regression of the tumour.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11258255.001).
  • [ISSN] 0041-5782
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Park YM, Cho JH, Cho JY, Huh JS, Ahn JY: Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy. World J Surg Oncol; 2007;5:86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy.
  • BACKGROUND: Solitary involvement of the sphenoid sinus has rarely been reported in non-Hodgkin's lymphoma.
  • Magnetic Resonance Imaging (MRI) demonstrated a homogenous soft-tissue lesion occupying the left sphenoid sinus and invading the left cavernous sinus.
  • The patient underwent transsphenoidal biopsy and the lesion was histologically diagnosed as non-Hodgkin's lymphoma, diffuse large B-cell type.
  • Following six cycles of chemotherapy, the left oculomotor nerve palsy that had been previously observed was completely resolved.
  • CONCLUSION: It is important to recognize that non-Hodgkin's lymphoma of the sphenoid sinus can present with isolated oculomotor nerve palsy, although it is extremely rare.
  • The cranial nerve deficits can resolve dramatically after chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Oculomotor Nerve Diseases / etiology. Paranasal Sinus Neoplasms / complications. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochirurgie. 2002 Dec;48(6):522-6 [12595809.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Acta Neurol Belg. 2000 Jun;100(2):103-6 [10934562.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Am J Ophthalmol. 2000 Feb;129(2):256-8 [10682985.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 May;120(5):730-6 [10229601.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Radiology. 1997 Aug;204(2):431-5 [9240531.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1995;112(6):298-302 [8561414.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Apr;102(4 Pt 1):318-21 [8476174.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] No Shinkei Geka. 1992 Mar;20(3):283-7 [1557180.001]
  • [Cites] Radiology. 1988 Jun;167(3):803-8 [3363145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Am J Clin Pathol. 1984 Jun;81(6):721-7 [6547270.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1925-31 [7427898.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):11-9 [12633576.001]
  • [Cites] Cancer. 1978 Aug;42(2):406-16 [679145.001]
  • (PMID = 17683562.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950883
  • [General-notes] NLM/ Original DateCompleted: 20070828
  •  go-up   go-down


25. Iida K, Tsutsumi M, Ishikawa S: [Metachronous primary malignant lymphoma of the bilateral tests: a case report]. Hinyokika Kiyo; 2002 Feb;48(2):93-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous primary malignant lymphoma of the bilateral tests: a case report].
  • We report a case of metachronous malignant lymphoma of the bilateral testes.
  • The histological examination confirmed non-Hodgkin's lymphoma of diffuse, large-sized cells of the B cell type.
  • Computed tomography of the abdomen revealed paracaval lymphandenopathy at stage IIE according to Ann Arbor classification.
  • Chemotherapy was initiated with cyclophosphamide, adriamycin and vincristine.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968735.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


26. Hokett SD, Cuenin MF, Peacock ME, Thompson SH, Van Dyke TE: Non-Hodgkin's lymphoma and periodontitis. A case report. J Periodontol; 2000 Mar;71(3):504-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma and periodontitis. A case report.
  • BACKGROUND: We describe an unusual case of extra-nodal non-Hodgkin's lymphoma that developed in the maxillae associated with localized severe periodontitis in a 64-year-old Caucasian male.
  • The lymphoma was diagnosed less than 2 years following routine periodontal surgery and 8 weeks after the extraction of hopeless teeth in the associated area.
  • A definitive biopsy diagnosis of high-grade, small, non-cleaved, diffuse non-Hodgkin's lymphoma of the right posterior maxillae was established.
  • The patient was subsequently treated by a combination of radiation, chemotherapy, and bone marrow transplantation.
  • RESULTS: The maxillary tissues healed uneventfully, and the patient has been closely observed for approximately 5 years without symptoms or recurrence of the lymphoma.
  • CONCLUSIONS: This case highlights the need for careful debridement of extraction sockets associated with severe periodontitis and argues for the routine submission of extracted teeth with adjacent soft tissue for microscopic analysis, to assist in the early diagnosis of potentially life-threatening malignancies.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Maxillary Sinus Neoplasms / complications. Periodontitis / etiology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Periodontal Abscess / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10776941.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T: Cytotoxic T-cell lymphoma arising in Behçet disease. Int J Hematol; 2003 Apr;77(3):282-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic T-cell lymphoma arising in Behçet disease.
  • The case of a 49-year-old man with peripheral T-cell lymphoma arising in Behcet disease (BD) is reported.
  • A left perirenal mass emerged, and a computed tomography-guided needle biopsy of the tumor revealed the infiltration of small- and medium-sized lymphoma cells.
  • A diagnosis of non-Hodgkin's lymphoma (diffuse medium, T-cell) was made.
  • Standard combination chemotherapy diminished the perirenal and orbital lesions.
  • Lymphoma cell infiltration in the esophagus was detected after chemotherapy, and the patient died of massive bleeding from the gastrointestinal tract.
  • Non-Hodgkin's lymphoma is rarely associated with BD, and only 7 cases have been reported in the literature.
  • We have summarized the published case reports of malignant lymphoma arising in BD.
  • To our knowledge, this case report is the first to describe cytotoxic T-cell lymphoma arising in Behçet disease.
  • [MeSH-major] Behcet Syndrome / complications. Lymphoma, T-Cell / etiology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Antigens, CD / analysis. Clone Cells / immunology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):241-5 [9085175.001]
  • [Cites] Ann Rheum Dis. 2001 Nov;60(11):996-1002 [11602462.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):317-26 [10830738.001]
  • [Cites] Arthritis Rheum. 1974 Jul-Aug;17(4):383-90 [4604718.001]
  • [Cites] No To Shinkei. 1992 Nov;44(11):1029-33 [1296716.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):296-301 [10680899.001]
  • [Cites] Int J Tissue React. 1988;10(2):59-65 [3053482.001]
  • [Cites] Ann Dermatol Venereol. 1990;117(11):885-7 [2099715.001]
  • [Cites] N Engl J Med. 1999 Oct 21;341(17):1284-91 [10528040.001]
  • [Cites] Ann Intern Med. 1976 Jan;84(1):68-76 [1106291.001]
  • [Cites] Intern Med. 1993 Aug;32(8):663-7 [8312668.001]
  • [Cites] Clin Rheumatol. 2001;20(4):239-44 [11529628.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):193-207 [10697278.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):313-23 [9578080.001]
  • [Cites] Rinsho Ketsueki. 1992 Feb;33(2):211-5 [1635171.001]
  • [Cites] Ann Rheum Dis. 1986 Sep;45(9):789 [3767471.001]
  • [Cites] Acta Pathol Jpn. 1974 Jan;24(1):141-50 [4406401.001]
  • [Cites] Arthritis Rheum. 1982 Nov;25(11):1343-51 [6215926.001]
  • [Cites] Arthritis Rheum. 1982 Sep;25(9):1130-3 [7126297.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Oct;236(10):798-9 [9801898.001]
  • [Cites] Rinsho Ketsueki. 1997 Aug;38(8):657-62 [9311271.001]
  • [Cites] Nephron. 1999 Feb;81(2):239 [9933762.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1728-33 [8826934.001]
  • (PMID = 12731673.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunosuppressive Agents
  • [Number-of-references] 25
  •  go-up   go-down


28. Miyazaki T, Fujimaki K, Shirasugi Y, Yoshiba F, Ohsaka M, Miyazaki K, Yamazaki E, Sakai R, Tamaru J, Kishi K, Kanamori H, Higashihara M, Hotta T, Ishigatsubo Y: Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol; 2007 Dec;82(12):1106-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
  • Rheumatoid arthritis (RA) is associated with an increased risk of developing lymphoma.
  • We investigated the relationship between EBV latent infection and methotrexate (MTX)-associated lymphoma in RA patients.
  • Nine patients were diagnosed with non-Hodgkin's lymphoma (NHL) during MTX treatment for RA in a multicenter study.
  • The pathologic findings were consistent with diffuse large B-cell lymphoma in 8 patients and peripheral T-cell lymphoma, unspecified in 1.
  • Further examination of the latent EBV infection patterns revealed that 2 patients who obtained a CR had latency Type III, and the other with SD had latency Type II.
  • These results demonstrate that immunodeficiency caused by MTX treatment is associated with the development of EBV-related NHL in RA patients.
  • In patients who were treated by MTX for RA and developed NHL, remission can be observed following MTX withdrawal especially in NHL with latency Type III EBV infection.
  • The analysis of EBV infection, including the latency types, is useful to decide the optimum therapeutic strategy.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / drug therapy. Epstein-Barr Virus Infections / complications. Lymphoma, Non-Hodgkin / chemically induced. Methotrexate / therapeutic use
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Treatment Outcome


29. Hashizume T, Fujimoto H: [Pyothorax associated lymphoma with increased neuron-specific enolase level in serum and pleural effusion: a case report]. Kekkaku; 2004 May;79(5):361-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pyothorax associated lymphoma with increased neuron-specific enolase level in serum and pleural effusion: a case report].
  • The computed tomography image showed a tumor mass arising from the wall of chronic pyothorax.
  • The tumor was 7.2 x 7.0 x 3.0 cm in size and the pathological diagnosis was non-Hodgkin's lymphoma diffuse large cell, B-cell type.
  • Postoperative chemotherapy and radiation therapy were performed but he died of recurrence and metastasis of the tumor 5 months later after the operation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Empyema, Pleural / complications. Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Phosphopyruvate Hydratase / analysis. Pleural Effusion / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15211877.001).
  • [ISSN] 0022-9776
  • [Journal-full-title] Kekkaku : [Tuberculosis]
  • [ISO-abbreviation] Kekkaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


30. Takauchi K, Kono H, Ito T, Zaima K, Okumoto S: [A case of primary hepatic lymphoma successfully treated by THP-COP therapy]. Nihon Ronen Igakkai Zasshi; 2003 Jan;40(1):65-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepatic lymphoma successfully treated by THP-COP therapy].
  • The presence of a tumor mass in the umbilical portion of the liver was recognized by abdominal ultrasonography and computed tomography scan.
  • Needle biopsy of the tumor showed non Hodgkin's lymphoma (diffuse large B cell type) by histology and histoimmunology.
  • Primary hepatic lymphoma is so infrequent that standard treatments are not established yet.
  • Most cases of primary hepatic lymphoma are treated by surgical resection in Japan; however our conservative approach to remission is considered as very helpful for discussing how to treat primary hepatic lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Female. Humans. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649851.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


31. Sakata K, Fuwa N, Kodaira T, Aratani K, Ikeda H, Takagi M, Nishio M, Satoh M, Nakamura S, Satoh H, Hareyama M: Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol; 2006 May;79(2):179-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: This study was conducted to analyze the influence of radiotherapy doses and chemotherapy doses and clinical parameters on in-field disease control in order to assess the optimal radiation doses for treatment of mature T/NK-cell lymphomas according to the newly proposed WHO classification.
  • We reevaluated all histopathological specimens of non-Hodgkin's lymphomas (NHL), using the WHO classification.
  • Radiation therapy was usually delivered to the involved field.
  • The majority of patients also received adriamycin-based chemotherapy such as CHOP, modified CHOP, or more intensive chemotherapy.
  • RESULTS: There were no significant differences in radiosensitivity among subtypes of mature T/NK-cell lymphomas, at least between extranodal NK/T-cell lymphomas, nasal type and peripheral T-cell lymphomas, unspecified.
  • There was a radiation dose-response in non-bulky mature T/NK-cell lymphomas, indicating that radiation doses of more than 52 Gy may be required to obtain in-field control.
  • CONCLUSIONS: Mature T/NK-cell lymphomas were more radioresistant than B-cell lymphomas such as diffuse large B-cell lymphomas (DLBCL).
  • The chemotherapy including adriamycin did not improve the in-field control of mature T/NK-cell lymphomas.
  • These results were obtained by using non-randomized data and the significance of these results is limited by bias in data.
  • However, our results suggest that the treatment strategy which is usually used for DLBCL, that is, a combined modality of CHOP and around 40 Gy of radiotherapy, may not be sufficiently effective for mature T/NK-cell lymphomas.
  • [MeSH-major] Lymphoma, T-Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644044.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


32. Yokoyama J, Fujimiya Y, Yamaguchi T, Shiga K, Saijo Y, Groveman DS, McBain JA, Suzuki Y, Ebina T: Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma. Am J Hematol; 2003 May;73(1):1-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult lymphoma cells prevalent in autologous marrow from non-Hodgkin's diffuse lymphoma.
  • The most effective treatment for recurrent non-Hodgkin's lymphoma (NHL) appears to be a high-dose cytotoxic chemotherapy (HDC) followed by autologous bone marrow transplantation (ABMT).
  • However, it has been suggested that the presence of occult lymphoma cells in harvested marrow may be responsible for a significant fraction of treatment failures after HDC/ABMT.
  • Among 41 NHL patients examined, bcl-2/IgH translocations were evident in LN biopsies and marrow from each of 10 follicular lymphoma patients, but not in any samples from 31 newly diagnosed diffuse lymphoma patients.
  • Such outgrowth was specifically seen in cultures of diffuse lymphoma marrow (7 of 28 evaluable patients).
  • Southern analysis for IgH rearrangement within LN biopsies and of cells cultured from marrow of individual diffuse lymphoma patients produced identical patterns, suggesting that the occult lymphoma cells present in harvested marrow were derived from the predominant lymphoma cell population represented within involved lymph nodes.
  • The culture of histologically occult lymphoma from diagnostic marrow and analysis of the derived cells by Southern blot hybridization can be used to detect potentially aggressive lymphoma cells within harvested marrow, despite their lack of bcl-2 gene rearrangement.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autoradiography. Biopsy. Blotting, Southern. Bone Marrow / pathology. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. DNA, Neoplasm / analysis. Deoxyribonuclease BamHI. Deoxyribonuclease EcoRI. Deoxyribonuclease HindIII. Female. Gene Rearrangement. Genes, bcl-2 / genetics. Genetic Markers. Humans. Immunoglobulin Heavy Chains / genetics. Lymph Nodes / pathology. Lymphoma, Follicular / genetics. Male. Middle Aged. Polymerase Chain Reaction. Translocation, Genetic. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12701113.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / Immunoglobulin Heavy Chains; EC 3.1.21.- / Deoxyribonuclease BamHI; EC 3.1.21.- / Deoxyribonuclease EcoRI; EC 3.1.21.- / Deoxyribonuclease HindIII
  •  go-up   go-down


33. Shimatani H, Furukawa K, Ebihara Y, Serizawa H, Tsuboi M, Ogata A, Konaka C, Kato H: An early stage diffuse B-cell lymphoma within a visible site of bronchofiberscope accompanied by peripheral lung cancer. Diagn Ther Endosc; 2000;6(4):179-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An early stage diffuse B-cell lymphoma within a visible site of bronchofiberscope accompanied by peripheral lung cancer.
  • We report a case of non-Hodgkin's lymphoma found at the orifice of right B2 accompanied by peripheral lung cancer in a 66-year-old asymptomatic man.
  • The biopsy specimen from that site showed non-Hodgkin's lymphoma (diffuse B-cell type).
  • After left lower lobectomy, systemic chemotherapy was performed.
  • It is rare for malignant lymphoma to be recognized bronchofiberscopically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493536.001).
  • [ISSN] 1070-3608
  • [Journal-full-title] Diagnostic and therapeutic endoscopy
  • [ISO-abbreviation] Diagn Ther Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2362766
  •  go-up   go-down


34. Kang KM, Chung WC, Lee KM, Hur SE, Nah JM, Kim GH, Back JY, Kim SK, Yang JM, Choi HJ: [A case of primary hepatic lymphoma mimicking hepatitis]. Korean J Hepatol; 2005 Sep;11(3):284-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary hepatic lymphoma mimicking hepatitis].
  • We report here on a case of non-Hodgkin's lymphoma in which liver involvement was the predominant clinical manifestation.
  • The abdominal CT scan showed only diffuse hepatosplenomegaly and uneven contrast enhancement of the spleen without any definite mass of the liver and spleen.
  • US-guided aspiration biopsy of liver and the histologic examination confirmed a diagnosis of non-Hodgkin's lymphoma, the diffuse large B cell type.
  • Bone marrow biopsy showed the infiltration of malignant lymphoma cells.
  • The patient was treated with combination regimen of cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy.
  • Even in the absence of a mass lesion or lymphadenopathy, primary hepatic or hepatosplenic lymphoma should be considered in differential diagnosis of hepatitis or liver cirrhosis, especially for patients with diffuse hepatosplenomegaly and markedly elevated LDH.
  • [MeSH-major] Hepatitis / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177555.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


35. Ogino J, Kawakatsu C, Hirasawa A, Sato T, Kawamura S, Nishikawa T, Wakabayashi Y: [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade]. Rinsho Ketsueki; 2001 Nov;42(11):1101-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade].
  • Abdominal ultrasonography and computed tomography revealed bilateral renal tumors.
  • Percutaneous needle biopsy of the left renal tumor was performed, and the final diagnosis was non-Hodgkin's lymphoma (diffuse mixed, B cell type, CSIIA).
  • After six courses of chemotherapy, the tumor lesions were markedly reduced, and at present there is no evidence of recurrence.
  • [MeSH-major] Hematuria / etiology. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808078.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Suzuki K, Sai S, Kato K, Murase T: [A case of malignant lymphoma of the epididymis]. Hinyokika Kiyo; 2000 Apr;46(4):291-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma of the epididymis].
  • Histologically, the tumor was diagnosed as a malignant lymphoma (non-Hodgkin's lymphoma, diffuse mixed cell type, B-cell type).
  • After establishment of the diagnosis of primary epididymal malignant lymphoma, 3 courses of chemotherapy (adriamycin, vincristine, cyclophosphamide, prednisolone) were performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Epididymis. Lymphoma, B-Cell / surgery. Lymphoma, Non-Hodgkin / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Orchiectomy. Prednisolone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10845166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 9
  •  go-up   go-down


37. Copson E: Non-Hodgkin's lymphoma (diffuse large B cell lymphoma). Clin Evid; 2005 Jun;(13):1-18
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Prednisone / administration & dosage. Rituximab. Salvage Therapy. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Clin Evid. 2006 Jun;(15):30-44 [16973004.001]
  • (PMID = 16135258.001).
  • [ISSN] 1462-3846
  • [Journal-full-title] Clinical evidence
  • [ISO-abbreviation] Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 33
  •  go-up   go-down


38. Copson E: Non-Hodgkin's lymphoma (diffuse large B cell lymphoma). Clin Evid; 2006 Jun;(15):30-44
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Prednisone / therapeutic use. Rituximab. Salvage Therapy. Stem Cell Transplantation. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Clin Evid. 2005 Jun;(13):1-18 [16135258.001]
  • (PMID = 16973004.001).
  • [ISSN] 1462-3846
  • [Journal-full-title] Clinical evidence
  • [ISO-abbreviation] Clin Evid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 35
  •  go-up   go-down






Advertisement